SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

PPD sells biomarkers biz to Caprion

25-Jan-2010 - US CRO PPD has sold its biomarker discovery sciences unit to Caprion Proteomics, bucking the trend that has seen many of its sector rivals invest in this part of the...

Quotient: GE deal secures customers' 14C supply ahead of Cardiff move

20-Jan-2010 - Quotient Bioresearch has secured the supply of 14C labelled compounds for its customers ahead of its move to a new purpose built facility in Cardiff through an extension of its...

Siro plans European growth; updates on Omega integration

13-Jan-2010 - Indian CRO Siro Clinpharm has renamed its European units and plans to open offices in two more countries in the region in the next few months.

News in brief

Trial IRBs ERC and IRB to merge

11-Jan-2010 - US clinical trial review groups Independent Review Consulting (IRC) and Ethical Review Committee (ERC) are to merge and operate under the name Ethical and Independent Review Services (E&I).

CBI and GL merger to create world’s largest preclinical peptide supplier

05-Jan-2010 - US CRO Commonwealth Biotechnologies (CBI) is moving forward with plans to buy Chinese peptide supplier GL Biochem.

Rexam to close Nashua plant; appoints new CEO

04-Jan-2010 - Rexam will close its pill and tablet bottle making facility in New Hampshire, US by the end of the year to further align global plastics operations according to new CEO...

Delays, takeover bids and Puerto Rico hurt 09, but Patheon up about 2010

22-Dec-2009 - Patheon says a slowdown in “outsourcing decision making,” manufacturing problems in Puerto Rico and cost related to JLL’s takeover bid hurt it in fiscal 09.

NexMed stays on Nasdaq after Bio-Quant buy

21-Dec-2009 - US drugmaker NexMed has maintained its place on the Nasdaq Stock Exchange, partly as a result of its acquisition of US preclinical CRO Bio-Quant.

Recipharm moves for Cobra to boost biologics capacity

17-Dec-2009 - Swedish CDMO Recipharm will buy privately-owned group Cobra Biomanufacturing to build its presence in the expanding biologics sector.

News in brief

Celesio buys Irish contract sales group Alchemy

09-Dec-2009 - German drug distribution and pharmacy firm Celesio has bought Ireland’s Alchemy Healthcare to drive its growth in the country’s contract sales sector.

Patheon & JLL enter into litigation settlement

01-Dec-2009 - Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting...

Few pharma plants will be sold to CMOs; report

26-Nov-2009 - The recent wave of M&A will lead to manufacturing over-capacity at pharma companies but only a small number of these sites will be sold to CMOs, in part because of...

NexMed to buy CRO Bio-Quant to boost Nasdaq compliance bid

25-Nov-2009 - US pharmaceutical firm NexMed hopes the planned acquisition of preclinical CRO Bio-Quant will help maintain its Nasdaq listing.

Icon eyeing China

24-Nov-2009 - Icon is looking to expand its bioanalytical capacity in Asia, notably in China, and bolster its genomics, proteomics and cell-based assay capabilities, according to a VP who discussed diversification of...

MDS’ Central Labs becomes Clearstone Central Laboratories

02-Nov-2009 - MDS’ Central Labs has been rebranded as Clearstone Central Laboratories following its acquisition by Czura Thornton, which is looking to expand the business and that of Chiltern, a CRO also...

MDS to sell Central Labs to Chiltern owner

12-Oct-2009 - MDS Pharma Services’ Central Labs division is to be acquired by Czura Thornton, a private investment group that owns Chiltern, for approximately $8m (€5.4m) as part of the CRO’s repositioning....

CPhI 2009 show preview

08-Oct-2009 - We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.

CRO market will have a healthier 2010; MDS

11-Sep-2009 - The outsourcing “market is poised to return to healthier growth rates in 2010”, according to the president of MDS Pharma Services who also told Outsourcing-Pharma that CROs will play an...

Patheon overview - a look at what Lonza would gain

10-Sep-2009 - With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.

B-MS outsources manufacture of products in 5 year deal

08-Sep-2009 - Bristol-Myers Squibb (B-MS) has outsourced the manufacture of some of its products to Sigma Pharmaceuticals, an Australia-based company that also bought a facility from the big pharma for A$60m ($51.7m)....

Cloud Packaging meets shorter run trend with Toll takeover

07-Sep-2009 - Cloud Packaging Solutions has said the acquisition of Toll Packaging will boost its ability to meet the increased demand for shorter packing runs triggered by the current global economic crisis.

Averion plans going private to cut outgoings

07-Sep-2009 - CRO Averion is planning to become a private company to reduce expenditure on auditor fees, which could realise savings of $805,000 (€561,000), and allow management to better focus on long-term goals.

PharmaForm streamlined as Akela Pharma restructures

04-Sep-2009 - US contract services firm PharmaForm has cut its workforce to 65 employees in a restructuring plan that parent company Akela Pharma said optimises its client support infrastructure.

JLL says Lonza’s $460m Patheon bid is “hostile”

04-Sep-2009 - US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”

Evotec buys in India to quicken drug development services

04-Sep-2009 - By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are...